



1632#
#13
-dia
3/5/03
PATENT
ATTORNEY DOCKET NO. 00742/066001

Certificate of Mailing: Date of Deposit: February 26, 2003

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Elaine Fabrizio

Printed name of person mailing correspondence

Elaine Fabrizio
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thomas L. Benjamin et al. Art Unit: 1632
Serial No.: 09/812,633 Examiner: Q. Janice Li
Filed: March 19, 2001 Customer No.: 21559
Title: DIAGNOSING AND TREATING CANCER CELLS USING SAL2

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAR 03 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office Action on the merits, but before the mailing of a final Office Action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

Applicants hereby request that an initialed copy of the Form PTO-1449 submitted with the Information Disclosure Statement mailed on February 26, 2002 be returned with the next action.

If there are any other charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date:

February 20, 2003

Kristina Becker-Brady
Kristina Becker-Brady, Ph.D.

Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

Sheet 1 of 1

| | | | | | | | |
|---|--|--|-----------------------------|---------------------|----------|---------------------------------|--|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | Attorney Docket No. | | 00742/066001 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | Serial No. | | 09/812,633 | |
| | | | | Applicant | | Thomas L. Benjamin et al. | |
| | | | | Filing Date | | March 19, 2001 | |
| | | | | Group | | 1632 | |
| | | | | IDS Filed | | February 20, 2003 | |
| (37 C.F.R. § 1.98(b)) | | | | Customer No. | | 21559 | |
| U.S. PATENTS | | | | | | | |
| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION | | | | | | | |
| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | | | | | | | |
| | Deonaran, "Ligand-Targeted Receptor-Mediated Vectors for Gene Delivery," <i>Exp. Opin. Ther. Patents</i> 8:53-59 (1998). | | | | | | |
| | Eck and Wilson, "Chapter 5: Gene-Based Therapy," in Goodman & Gilman's <i>The Pharmacological Basis of Therapeutics</i> , 9th Edition, McGraw-Hill, pp. 77-101 (1995). | | | | | | |
| | Miller and Vile, "Targeted Vectors for Gene Therapy," <i>FASEB J.</i> 9:190-199 (1995). | | | | | | |
| | Verma and Somia, "Gene Therapy - Promises, Problems and Prospects," <i>Nature</i> 389:239-242 (1997). | | | | | | |
| | Vinyls et al., "Failure of Wild-Type p53 Gene Therapy in Human Cancer Cells Expressing a Mutant p53 Protein," <i>Gene Therapy</i> 6:22-33 (1999). | | | | | | |
| | Zink et al., "Mammalian Genome Organization and its Implications for the Development of Gene Therapy Vectors," <i>Gene Ther. Mol. Biol.</i> 6:1-24 (2001). | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| The next communication to applicant | | | | | | | |

RECEIVED

MAR 13

TECH CENTER 1600/2900